IAVI Report

In a few weeks, the AIDS 2018 meeting will kick off in Amsterdam. It will be the 22nd annual conference, and remains the largest international gathering focused on a single public health issue. This year, one message that will come out loud and clear is that more than 30 years later, AIDS isn’t over. As…

Marianne Mureithi is part of a team of researchers that just received highly competitive funding to study mucosal immune responses to HIV in Kenya.

Drone delivery may help overcome the challenge of getting medicines and vaccines to hard-to-reach populations.

Maria Grazia Pau, senior director, compound development team leader for HIV vaccine programs at the Janssen Pharmaceutical Companies of Johnson & Johnson, talks with IAVI Report about the start of the company’s Phase III Mosaico trial.

Over hundreds of years, researchers have matched contemporary scientific tools to address the infectious disease threats of their times.

A slew of potential advances in treating and preventing tuberculosis offers new hope in the battle against one of the oldest human afflictions.

Regulatory approval of a vesicular stomatitis virus-based vaccine paves the way for use of this viral vector in other vaccines.

Africa is contributing far more than samples to scientific research. The continent’s scientists are actively engaged in developing and testing novel HIV vaccine candidates.

A conversation with Anatoli Kamali and Penny Moore about the rise of HIV vaccine science in Africa

This year’s flu season was one for the books, and it swung the spotlight directly on vaccines. The predominant strain of influenza virus that circulated in the US, an influenza A subtype known as H3N2, was particularly virulent, leaving thousands dead and sending many more to the hospital. And the seasonal flu vaccine was only…

If you are a regular IAVI Report reader, it will come as no surprise that antibodies, particularly those that are both potent and able to neutralize a broad swath of global HIV isolates, are all the rage. Such antibodies have been isolated in droves from HIV-infected people and are now fueling vaccine design efforts. They are also being…

 In 2007, I was in Cape Town to attend a symposium on the challenges of global vaccine development. At that meeting, and during my visits to nearby clinical research centers, the mood was somber. Just weeks before, two HIV vaccine efficacy trials, known as STEP and Phambili, had ground to a halt. These trials were testing…